Special Issue "Asthma: From Phenotypes to Personalized Medicine"
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 26847
Asthma is a heterogenous disease of the airways with a high prevalence worldwide and characterized by chronic inflammation. The aim of asthma management is the control of the disease, and the cornerstone of asthma treatment is inhaled corticosteroids. Asthma is no longer recognized as a unique manifestation and the “one size fits all” approach may apply only in the treatment of mild asthma. As asthma becomes less well-controlled and more severe (moderate-to-severe), medications are more or less effective in particular phenotypes. Phenotypes and endotypes are known, respectively, as pathologic and molecular features that might not be directly associated with each other but may define a better response to treatment, and that is important from a clinical point of view. Accordingly, it has become necessary to define the phenotype of an asthmatic patient mainly based upon biomarkers and clinical features, and this has led to treatable traits and personalized medicine. Each asthmatic, and especially severe ones, is evaluated in terms of their phenotype, followed by the initiation of a treatment regimen that would be more effective in improving symptoms and/or reducing exacerbations, both of which are considered measures of control. In this Special Issue, we will focus on the various asthma phenotypes and assess how these phenotypes lead to personalized medicine.
Prof. Dr. Petros Bakakos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- asthma phenotype
- asthma endotype
- allergic asthma
- eosinophilic asthma
- personalized medicine